Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
- The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
- “Our IND submission for CTIM-76 is a significant milestone for Context,” said Martin Lehr, CEO of Context.
- The IND application includes extensive manufacturing, preclinical, and toxicology data to support a first-in-human trial.
- I am incredibly proud of the entire Context team who worked tirelessly to complete this IND submission.